Anti-TPO: Antithyroidal Antibodies With or Without Subclinical Hypothyroidism During Pregnancy in Infertile Women

Sponsor
University Hospital, Basel, Switzerland (Other)
Overall Status
Completed
CT.gov ID
NCT04249271
Collaborator
(none)
96
1
22.9
4.2

Study Details

Study Description

Brief Summary

One prospective observational study was carried out in 2009 aiming at identifying the fluctuations of the thyroid hormones in women with normal thyroid gland and in women with anti-TPO antibodies. Serum samples were collected periodically during and after pregnancy in previously infertile women. The samples were stored frozen at -80 °C. Now, the hormone measurements will be carried out.

Condition or Disease Intervention/Treatment Phase
  • Other: serum sampling

Detailed Description

Exclusion of thyroid disease has long been an integral part of a comprehensive infertility work-up, because thyroid function disorders are also associated with disturbances in the menstrual cycle and can cause complications during pregnancy. Subclinical hypothyroidism is the most frequent disease of the thyroid in women of reproductive age (affecting 5 to 10 %). For a long time, measurement of TSH concentration was the only screening parameter used to exclude thyroid disorders. Not only has the differentiation of normal thyroid function (euthyroidism) from the pathological range been controversial for some years but, recently, the role of an elevated anti-TPO antibody titre has also been identified as a significant and independent risk factor for miscarriages and for complications during late pregnancy, even in otherwise euthyroid women. This discovery implies that solely determining the TSH concentration is insufficient. The mechanism underlying the increased rate of complications during pregnancy is also unclear.

The investigators therefore performed a double study to clarify the relative importance of the various possible parameters of thyroid function in the context of an infertility work-up:

  1. Prevalence study: Measurement of TSH and anti-TPO concentrations in 175 women who present with infertility at the Infertility Clinic at the Women's Hospital, University Hospital Basel. In addition, each participant underwent an ultrasound scan of the thyroid. Control group: 175 healthy women of reproductive age and with regular menstrual cycles, but not currently wishing to have children (recruited via posters in the university and Blood Donor Centre). This study has been finished in 2010. The data of the prevalence study were used to carry out the prospective sampling of the serum samples.

  2. Prospective measurement of fluctuations in thyroid function during pregnancy and post-partum in a group of euthyroid women and/or those with subclinical hypothyroidism (TSH > 4.5 mIU/l) with/without anti-TPO antibodies. Two different euthyroid groups were defined for the study: Euthyroidism I = TSH 0.3-2.5 mIU/l; Euthyroidism II = TSH 2.5-4.5 mIU/l. Six groups, each with 16 women, divided according to TSH concentration and anti-TPO antibody status, will be required (total 96). All female participants with subclinical hypothyroidism (TSH concentration > 4.5 mIU/l, normal values of peripheral thyroid hormones) receive a T4 supplementation dose. Serum samples will be collected each week from the start of pregnancy up to the 12th week and stored frozen at -80 °C. Thereafter, a serum sample will be collected once a month (up to the 38th week) and stored frozen at -80 °C. Finally, one serum sample post-partum (4 to 6 weeks after delivery) and freeze it. A total of 96 women (16 in each group) were recruited to participate in this study.

After conclusion of the observation period, levels of the following hormones will be measured in the total of 1120 serum samples: TSH, total and free l-thyroxine and fT4 index, total and free triiodothyronine, thyroid autoantibodies (TPO antibodies), hCG, 17β-oestradiol, progesterone, prolactin.

Study Design

Study Type:
Observational
Actual Enrollment :
96 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Antithyroidale Antikörper Mit Oder Ohne Subklinische Hypothyreose Bei Weiblicher Infertilität in Der Schwangerschaft Und im Wochenbett.
Actual Study Start Date :
Feb 1, 2018
Actual Primary Completion Date :
Dec 31, 2019
Actual Study Completion Date :
Dec 31, 2019

Arms and Interventions

Arm Intervention/Treatment
euthyroid, no antibodies

TSH 0.3 to 2.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling

Other: serum sampling
repeated serum sampling during pregnancy and thereafter

borderline euthyroid, no antibodies

TSH 2.5 to 4.5 mIU/l and anti-TPO <100 IU/l repeated serum sampling

Other: serum sampling
repeated serum sampling during pregnancy and thereafter

hypothyroidism, no antibodies

TSH >4.5 mIU/l and anti-TPO <100 IU/ml repeated serum sampling

Other: serum sampling
repeated serum sampling during pregnancy and thereafter

euthyroid, with antibodies

TSH 0.3 to 2.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling

Other: serum sampling
repeated serum sampling during pregnancy and thereafter

borderline euthyroid, with antibodies

TSH 2.5 to 4.5 mIU/l and anti-TPO >100 IU/l repeated serum sampling

Other: serum sampling
repeated serum sampling during pregnancy and thereafter

hypothyroidism, with antibodiesal

TSH >4.5 mIU/l and anti-TPO >100 IU/ml repeated serum sampling

Other: serum sampling
repeated serum sampling during pregnancy and thereafter

Outcome Measures

Primary Outcome Measures

  1. Deviations from euthyroid function as given by serum levels of TSH (expressed in mIU/l) during pregnancy and after birth. [12 months]

    Impact of antibodies on thyroid function during pregnancy.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • previous infertility with known thyroidal function (TSH, anti-TPO)
Exclusion Criteria:
  • other endocrine pathology, such as Addison, diabetes mellitus

  • manifest thyroidal pathology, such as Graves disease

  • contraindication against pregnancy

  • after repeated miscarriage (3 or more)

  • heavy smokers (20 cig per day or more)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Klinik für Gyn. Endokrinologie und Reproduktionsmedizin der Frauenklinik des Universitätsspitals Basel Switzerland 4031

Sponsors and Collaborators

  • University Hospital, Basel, Switzerland

Investigators

  • Principal Investigator: Christian De Geyter, Prof., University of Basel

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christian De Geyter, Prof., University Hospital, Basel, Switzerland
ClinicalTrials.gov Identifier:
NCT04249271
Other Study ID Numbers:
  • EKNZ 39-009 00960
First Posted:
Jan 30, 2020
Last Update Posted:
Jan 30, 2020
Last Verified:
Jan 1, 2020
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Christian De Geyter, Prof., University Hospital, Basel, Switzerland
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 30, 2020